Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for hematological, pulmonary and cardiovascular disorders. Co.'s protein therapeutic product candidate, KER-050, is developed for the treatment of low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Co.'s small molecule product candidate, KER-047, is developed for the treatment of functional iron deficiency. Co.'s third product candidate, KER-012, is developed for the treatment of pulmonary arterial hypertension, and for the treatment of cardiovascular disorders. The KROS YTD return is shown above.
The YTD Return on the KROS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KROS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KROS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|